GHK-Cu for Hair Growth: What the Evidence Actually Shows

Does GHK-Cu grow hair in people?

We found no human trial of GHK-Cu alone for hair growth. The human hair evidence we found is one uncontrolled scalp-injection study. The 2026 systematic review mapped GHK-Cu research published between 2005 and 2026: 1,247 records were identified and 64 were kept for synthesis. The authors write that most randomized trials are small, were run on facial cosmetic creams, and that microneedle delivery of GHK-Cu has not been evaluated in a single registered, adequately powered human randomized trial [10].

The scalp-injection study did not test GHK-Cu alone. Kapoor and Shome reported an open-label, single-arm pilot in 1,000 patients who received intradermal scalp injections of a formulation containing vascular endothelial growth factor, basic fibroblast growth factor, insulin-like growth factor, keratinocyte growth factor, thymosin beta-4 and copper tripeptide-1, once every three weeks for eight sessions. Hair fall on the pull test fell in 83% of patients, 75% said the injections helped their hair loss, and total hair count was still significantly higher at one year (P=0.002). There was no control group, and copper tripeptide-1 was one of six ingredients, so the result cannot be credited to GHK-Cu [2].

What the human GHK-Cu trials actually measured

Thirteen patients completed the randomized laser-resurfacing study in which patients received post-treatment skin care with or without GHK-Cu. Computer analysis and blinded evaluators found no significant difference between groups in how quickly redness resolved, in wrinkles, or in overall skin quality. A patient questionnaire did show a significant difference in overall skin quality favoring GHK-Cu (P=.04) [6].

Eighty-six evaluable patients completed the randomized venous-ulcer trial comparing a 0.4% tripeptide copper complex cream, silver sulfadiazine 1%, or an inert vehicle. The copper cream was no different from vehicle for ulcer size; silver sulfadiazine reduced ulcer size [7].

A third trial pointed the other way. In a multicenter, randomized, evaluator-blinded, placebo-controlled study of diabetic neuropathic foot ulcers, a GHK-Cu gel produced 98.5% median area closure versus 60.8% with vehicle (P<0.05) [8].

These trials measured skin healing or cosmetic appearance, not scalp hair.

The animal data behind the hair claim

Uno and Kurata reported that a copper-binding peptide, PC1031, caused follicular enlargement on the back skin of fuzzy rats, an effect the authors described as similar to topical minoxidil. The abstract does not name the peptide as GHK-Cu [1]. That model does not measure hair growth on a human scalp.

What is proposed as the mechanism

GHK is proposed to work as a copper complex. In laboratory and animal work summarized by the researchers who proposed the mechanism, GHK stimulates both the synthesis and the breakdown of collagen and glycosaminoglycans, modulates metalloproteinases and their inhibitors, attracts immune and endothelial cells to the site of an injury, and accelerates wound healing in dogs, rats, mice and pigs [5]. These are proposed and preclinical actions; they were not measured in a human hair follicle in the trials above.

Is any GHK-Cu product approved or regulated as a drug?

Under the FD&C Act, cosmetics and cosmetic ingredients do not need FDA approval before they are sold, so copper peptide serums and creams reach the market as cosmetics. Intended use decides the category: a claim that a product will restore hair growth makes it a drug [4]. No FDA-approved drug is known to contain GHK-Cu [3]. Copper histidinate (Zycubo) is a different compound, FDA-approved January 12, 2026 for Menkes disease in children [11].

Non-injectable GHK-Cu sits in category 1 on FDA's list for state-licensed pharmacies and physicians, the group under evaluation for the bulks list. FDA says it generally does not intend to act against compounders for category 1 substances when the conditions in its guidance are met [12], and it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 on whether to include GHK-Cu on the bulks list; no vote has taken place [3]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [13].

Injectable GHK-Cu appears in FDA's nominated but withdrawn table. FDA's stated concern: "Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations." [9]

Practical points on strength and use

No FDA-approved dose or product exists [3]. A venous-ulcer trial tested a 0.4% tripeptide copper complex cream [7]. A separate diabetic foot-ulcer trial tested GHK-Cu gel [8]. Neither establishes a dose for hair growth. Topical cosmetic strengths are set by manufacturers and are not reviewed by FDA [4].

HealthRX.com offers a copper peptide cream as a topical cosmetic. None of the trials above tested a GHK-Cu cream on the scalp for hair growth [6][7][8][2].